Abeona Therapeutics Doses First Patient in Phase 1/2 Trial With Abo-102 Gene Therapy For Patients With Sanfilippo Syndrome Type A

Abeona Therapeutics Inc. doses the first patient in a Phase 1/2 trial for ABO- 102, a single treatment gene therapy strategy for patients with Sanfilippo syndrome type A, at Nationwide Children’s Hospital in Columbus, Ohio.